Premium
THE ZOLLINGER–ELLISON SYNDROME: A REVIEW OF THE ST VINCENT'S HOSPITAL, MELBOURNE EXPERIENCE
Author(s) -
Vellar Dominic,
Henderson Michael,
Vellar Ivo D.,
Desmond Paul
Publication year - 1985
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1985.tb00923.x
Subject(s) - medicine , zollinger ellison syndrome , general surgery , gastrinoma , secretion , gastrin
Eight cases of the Zollinger–Ellison syndrome were diagnosed at St Vincent's Hospital in the period 1966–84. Although a rare tumour, its true incidence is almost certainly greater than the number of cases represented in this series. The Zollinger–Ellison syndrome should be suspected in all cases of recurrent peptic ulceration, in cases of peptic oesophagitis not responding to medical treatment, in some cases of diarrhoea and in those cases of peptic ulceration associated with hypercalcaemia. Rarely the gastrinoma may first present as a mass in the head of the pancreas causing obstructive jaundice. Diagnosis has been made easier by estimation of fasting serum gastrins and the use of the secretin test. Localization is difficult. The treatment of the condition remains contentious. In those cases shown to be harbouring a so‐called solitary gastrinoma, laparotomy should be performed with a view to resection. If the gastrinoma cannot be localized then it is reasonable to use H2 blocking agents to control hypersecretion. The presence of hypercalcaemia due to hyperparathyroidism must be controlled by parathyroidectomy. Total gastrectomy is reserved for those few cases who for one reason or another are not controlled by adequate H2 blocking therapy. In the presence of malignant gastrinoma with metastatic disease, hypersecretion is controlled by the use of H2 blocking agents. In this group cytotoxic chemotherapy may be used in an attempt to control the mass effects of the tumour.